Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi‐step model of myeloid leukaemogenesis

Children with Down syndrome (DS) have a marked increase in susceptibility to Acute Megakaryoblastic Leukaemia (DS‐AMKL) and the closely linked neonatal preleukaemic syndrome, Transient Myeloproliferative Disorder (DS‐TMD). The distinct stages of DS‐TMD and DS‐AMKL provide an excellent tractable model to study leukaemogenesis. This review focuses on recent studies describing clinical, haematological and biological features of DS‐AMKL and DS‐TMD. The findings from these studies suggest that mutations in the key haemopoietic regulator GATA1 (GATA binding protein 1) in DS‐AMKL and DS‐TMD may be useful in diagnosis and assessing minimal residual disease. These findings raise the possibility of population‐based screening strategies for DS‐TMD and the development of treatment to eliminate the preleukaemic TMD clone to prevent DS‐AMKL. Advances in our understanding of perturbed haemopoiesis in DS, the role of GATA1 and of cooperating mutations are also discussed. These findings have implications for leukaemia biology more broadly given the frequency of acquired trisomy in other human leukaemias.

[1]  N. Nowak,et al.  Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region , 2009, BMJ Case Reports.

[2]  J. Crispino,et al.  ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. , 2009, Blood.

[3]  S. Antonarakis,et al.  Genotype–phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21 , 2009, European Journal of Human Genetics.

[4]  S. Izraeli,et al.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. , 2009, Blood.

[5]  Elizabeth M.C. Fisher,et al.  Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome , 2009, Human molecular genetics.

[6]  K. Anderson,et al.  Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. , 2009, Blood.

[7]  K. Anderson,et al.  Specific JAK 2 mutation ( JAK 2 R 683 ) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia , 2009 .

[8]  J. Crispino,et al.  ETS 2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells , 2009 .

[9]  M. Weiss,et al.  Trisomy 21 enhances human fetal erythro-megakaryocytic development. , 2008, Blood.

[10]  P. Vyas,et al.  Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. , 2008, Blood.

[11]  A. Baruchel,et al.  Activating mutations in human acute megakaryoblastic leukemia. , 2008, Blood.

[12]  G. Wainreb,et al.  Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome , 2008, The Lancet.

[13]  Tomohiko Nakamura,et al.  Risk factors for early death in neonates with Down syndrome and transient leukaemia , 2008, British journal of haematology.

[14]  P. Vyas,et al.  Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML , 2008, Leukemia.

[15]  H. Kanegane,et al.  Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome , 2008, British journal of haematology.

[16]  D. Reinhardt,et al.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. , 2008, Blood.

[17]  B. Johansson,et al.  Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. , 2008, Blood.

[18]  M. L. Le Beau,et al.  Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. , 2008, Blood.

[19]  Sharon R. Pine,et al.  Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. , 2007, Blood.

[20]  P. Vyas,et al.  Haematology of Down syndrome , 2007, Archives of Disease in Childhood Fetal and Neonatal Edition.

[21]  P. Vyas,et al.  Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. , 2007, Blood.

[22]  P. Vyas,et al.  Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome , 2007, Nature Clinical Practice Oncology.

[23]  D. Reinhardt,et al.  Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome , 2007, Leukemia.

[24]  D. Nižetić,et al.  Loss‐of‐function JAK3 mutations in TMD and AMKL of Down syndrome , 2007, British journal of haematology.

[25]  P. Vyas,et al.  Molecular insights into Down syndrome-associated leukemia , 2007, Current opinion in pediatrics.

[26]  T. Naoe,et al.  JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults , 2007, Leukemia.

[27]  R. Christensen,et al.  Hematological abnormalities during the first week of life among neonates with Down syndrome: Data from a multihospital healthcare system , 2007, American journal of medical genetics. Part A.

[28]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[29]  A. F. Cunha,et al.  An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis , 2006, Nature Genetics.

[30]  John J Doyle,et al.  A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. , 2006, Blood.

[31]  G. Xu,et al.  Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome , 2006, Leukemia.

[32]  S. Winter,et al.  Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. , 2006, The Journal of pediatrics.

[33]  Eero Pukkala,et al.  Cancer incidence of persons with down syndrome in Finland: A population‐based study , 2006, International journal of cancer.

[34]  R. Hills,et al.  Treatment for myeloid leukaemia of Down syndrome: population‐based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials , 2006, British journal of haematology.

[35]  R. Reeves,et al.  Understanding the Basis for Down Syndrome Phenotypes , 2006, PLoS genetics.

[36]  Aravind Subramanian,et al.  Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Yubin Ge,et al.  Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. , 2006, Blood.

[38]  M. Weiss,et al.  Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. , 2005, Blood.

[39]  George A Calin,et al.  MicroRNA fingerprints during human megakaryocytopoiesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Hop,et al.  Intrinsic abnormalities of lymphocyte counts in children with down syndrome. , 2005, The Journal of pediatrics.

[41]  P. Vyas,et al.  GATA1-Mediated Megakaryocyte Differentiation and Growth Control Can Be Uncoupled and Mapped to Different Domains in GATA1 , 2005, Molecular and Cellular Biology.

[42]  Dean Nizetic,et al.  An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes , 2005, Science.

[43]  J. Crispino,et al.  Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. , 2005, Blood.

[44]  D. Reinhardt,et al.  AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity , 2005, Leukemia.

[45]  S. Orkin,et al.  Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.

[46]  D. Reinhardt,et al.  Immunophenotype of Down Syndrome Acute Myeloid Leukemia and Transient Myeloproliferative Disease Differs Significantly from Other Diseases with Morphologically Identical or Similar Blasts , 2005, Klinische Padiatrie.

[47]  G. Gustafsson,et al.  Acute leukaemia in children with Down syndrome: a population‐based Nordic study , 2005, British journal of haematology.

[48]  P. Vyas,et al.  GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder , 2005, British journal of haematology.

[49]  A. Gamis.  Acute myeloid leukemia and Down Syndrome evolution of modern therapy—state of the art review , 2005, Pediatric blood & cancer.

[50]  A. Olshan,et al.  Epidemiology of leukemia in children with Down syndrome , 2005, Pediatric blood & cancer.

[51]  J. Taub,et al.  Down syndrome, drug metabolism and chromosome 21 , 2005, Pediatric blood & cancer.

[52]  A. Zipursky,et al.  Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome , 2004, Leukemia.

[53]  D. Nižetić,et al.  Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker , 2004, British journal of haematology.

[54]  P. Vyas,et al.  Natural history of GATA1 mutations in Down syndrome. , 2004, Blood.

[55]  T. Naoe,et al.  Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome , 2003, Leukemia.

[56]  Y. Hayashi,et al.  Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. , 2003, Blood.

[57]  Y. Ravindranath.  Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  T. Alonzo,et al.  Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Teigler‐Schlegel,et al.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. , 2003, Blood.

[60]  S. Scherer,et al.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. , 2003, Blood.

[61]  Kamaleldin E Elagib,et al.  RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. , 2003, Blood.

[62]  D. Nižetić,et al.  Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder , 2003, The Lancet.

[63]  G. de Jong,et al.  Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks' gestation with Down syndrome: case report and review of the literature , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[64]  A. Zipursky,et al.  Transient leukaemia – a benign form of leukaemia in newborn infants with trisomy 21 , 2003, British journal of haematology.

[65]  I. Baumann,et al.  A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases , 2003, Leukemia.

[66]  R. Pieters,et al.  Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. , 2002, Blood.

[67]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[68]  R. Hanada,et al.  Distinctive Multidrug Sensitivity and Outcome of Acute Erythroblastic and Megakaryoblastic Leukemia in Children With Down Syndrome , 2001, International journal of hematology.

[69]  Nitin J. Karandikar,et al.  Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. , 2001, American journal of clinical pathology.

[70]  A. Baschat,et al.  Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21 , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[71]  R. Mohammad,et al.  Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. , 2000, Cancer research.

[72]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21 , 2000 .

[73]  B. Lange.  The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome , 2000, British journal of haematology.

[74]  A. Zipursky.  Susceptibility to Leukemia and Resistance to Solid Tumors in Down Syndrome , 2000, Pediatric Research.

[75]  G. Gustafsson,et al.  Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? , 2000, Leukemia.

[76]  F. Girodon,et al.  Immunophenotype of a transient myeloproliferative disorder in a newborn with trisomy 21. , 2000, Cytometry.

[77]  H. Hasle,et al.  Risks of leukaemia and solid tumours in individuals with Down's syndrome , 2000, The Lancet.

[78]  A. Zipursky,et al.  The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. , 2000, Cancer genetics and cytogenetics.

[79]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. , 2000, Blood.

[80]  Y. Ravindranath,et al.  Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. , 1999, Blood.

[81]  I. Roberts,et al.  Thrombopoietin Has a Primary Role in the Regulation of Platelet Production in Preterm Babies , 1999, Pediatric Research.

[82]  J. Buckley,et al.  Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. , 1998, Blood.

[83]  Y. Ravindranath,et al.  Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. , 1997, Leukemia.

[84]  J. Harbott,et al.  Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. , 1996, Leukemia.

[85]  J. Gurney,et al.  Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. , 1996, Blood.

[86]  M. Siimes,et al.  Peripheral blood cell counts in infants with Down's syndrome , 1996, Clinical genetics.

[87]  A. Valori,et al.  Hematological studies in children with Down syndrome. , 1996, Pediatric hematology and oncology.

[88]  J. Delabar,et al.  Molecular Mapping of Twenty-Four Features of Down Syndrome on Chromosome 21 , 1993, European journal of human genetics : EJHG.

[89]  T. Starc.  Erythrocyte macrocytosis in infants and children with Down syndrome. , 1992, The Journal of pediatrics.

[90]  H. Kurahashi,et al.  Mixed phenotype of blasts in acute megakaryocytic leukaemia and transient abnormal myelopoiesis in Down's syndrome , 1992, British journal of haematology.

[91]  A. Zipursky,et al.  Leukemia in Down syndrome: a review. , 1992, Pediatric hematology and oncology.

[92]  E. Niebuhr,et al.  Down's syndrome , 1974, Humangenetik.

[93]  J. Lejeune,et al.  [Study of somatic chromosomes from 9 mongoloid children]. , 1959, Comptes rendus hebdomadaires des seances de l'Academie des sciences.